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Abstract

Development of a targeted drug delivery system is a critical step in the effort

to improve cancer treatments. Such a system would greatly reduce the harmful side
effects of chemotherapy by delivering toxic drugs directly to cancerous cells.

Peptoids—synthetic compounds that can be easily produced from readily available
amine monomers—have great potential for use in targeted drug delivery. This

project aimed to develop peptoids that would bind to specific proteins expressed on
the surface of cancer cells. These peptoids could be combined into a complex that
would bind to the proteins with an even greater affinity than the individual
compounds. The peptoid complexes would serve as a targeting system for
chemotherapeutic drugs, delivering them directly to cancer cells, thereby

preventing healthy tissues from being harmed. The specific membrane proteins that

are being targeted are lectin-like oxidized low-density lipoprotein receptors (LOX-1)
and receptors for advanced glycation end-products (RAGE). Both LOX-1 and RAGE
are expressed in higher concentrations on cancerous cells than on non-cancerous
ones.

A combinatorial peptoid library was created using five side chains that have

been identified as being suitable for this application. Each peptoid is six monomers

long, resulting in a theoretical library diversity of 15,625 different compounds. A

small sample of the library was screened to qualitatively identify peptoids with the
highest binding affinity for LOX-1. To determine the sequences (chemical

structures) of the peptoids that displayed high LOX-1, an automated peptide

sequencer was utilized. Unfortunately, the time to work through the technicalities of

the sequencing process exceeded the length of the project-to-date. However,

progress was made and the sequences may be determined in the near future.

Eventually the process will be repeated to determine RAGE-binding peptoids and
the peptoids will be combined in a chemotherapy drug targeting system.

Introduction

It is often acknowledged that the side effects of chemotherapy treatment can

be as unpleasant as the cancer itself. These unwanted side effects are caused

because the toxic drugs used to destroy metastasized cancer cells are delivered

globally within the body, causing harm to both cancerous and healthy tissues alike
[1]. As such, much work has gone towards the development of so-called targeted

treatments for cancer. The basic idea behind targeted chemotherapy treatments is

that if anti-cancer drugs can be delivered directly to cancer cells while bypassing

healthy tissues, then the efficacy of the drugs will increase and their harmful side
effects will decrease.

One potential means of targeting therapeutics to cancer cells is to

encapsulate anti-cancer drugs within a microscopic structure, such as a

microbubble, that contains particular protein-binding molecules on its surface.

These molecules can be anything from antibodies to small-molecule ligands, but

regardless, they are selected or designed such that they bind with high specificity to
particular proteins that are expressed on the surface of the cancer cells being

targeted. Thus, for example, drug-containing microbubbles could be injected into a
patient’s blood stream, where if they came into contact with cells expressing the

protein being targeted, the microbubbles would stick to those cells. Some external
application such as high-frequency ultrasound could then be used to disrupt the

microbubbles, releasing the chemotherapy drugs into the immediate vicinity of the
cancer cells [2]. As such, many healthy tissues would be spared the destructive

effects of the drugs, whose side effects would then be greatly diminished.

In the present work, the first steps were taken towards developing just such

a system utilizing peptoids (poly-N-substituted glycines) as the targeting

compounds, i.e. the protein-binding molecules that would be on the outside of the

microbubble. Peptoids are very similar to naturally occurring peptides, except that
in peptoids the side chains are attached to the nitrogen instead of the α-carbon

(Figure 1). Additionally, the backbone of peptoids is achiral and the molecules do

not use hydrogen bonds to form secondary structures. Like peptides and antibodies,
peptoids can be designed to act as ligands for particular proteins; however, because
of their structural differences from peptides, peptoids are largely protease resistant

[3,4]. This makes peptoids promising compounds for use in in vivo applications,
such as targeting cancer cells.

Figure 1. General structures of peptides and peptoids.

A limitation in creating peptoids that specifically target cancer cells is that

the proteins on the surface of many cancerous cells are very similar to those of noncancerous ones. However, recent literature has indicated that lectin-like oxidized
low-density lipoprotein receptors (LOX-1) and receptors for advanced glycation

end-products (RAGE) are expressed at higher levels during metastasis of certain

cancers [5,6]. The increased expression of these membrane proteins can be taken
advantage of by creating a “bifunctional” peptoid complex that will attach to the

combination of LOX-1 and RAGE with high specificity (Figure 2). The work outlined

in this paper details efforts to design and optimize a peptoid that acts as a ligand for
LOX-1.

Figure 2. Diagram of the bifunctional peptoid targeting complex.

Methods and Materials

Unfortunately, it is unclear which peptoid chemistries should have the best

binding characteristics towards LOX-1. As such, a combinatorial peptoid library was
synthesized, which enabled the rapid screening of several thousand different

peptoid sequences for LOX-1 binding. Peptoids are synthesized on resin beads by
starting with a resin-bound amine group and reacting it with a haloacetic acid

(typically bromoacetic acid). The halogen is then replaced with the amine group of a

second “submonomer” (the side chain), thus adding another functional group to the

peptoid. The cycle is repeated until the desired peptoid sequence is achieved (Figure

3) [3,4]. All peptoids in the library were synthesized using a modified automated
peptide synthesizer.

Figure 3. General peptoid synthesis protocol.

The combinatorial peptoid library was created using five different side

chains that were chosen based on their performance in a previous study (Figure 4)
[4]. The peptoids were synthesized on Tenta-Gel Macrobead® resin using a mix-

and-split method such that the library was composed of 6-mer peptoids with every
combination of the five side chains (Figure 5). This resulted in a library with a
theoretical diversity of 15,625 (or 56) compounds.

Figure 4. Structures of the five side chains used to build the library.

Figure 5. Diagram of the mix-and-split method used to create the peptoid library.

The peptoids were screened for LOX-1 binding on their respective beads

using an adapted enzyme-linked immunosorbent assay (ELISA) protocol (Figure 6).

First, nonspecific protein binding was blocked for on the bead using a casein

solution. Then the beads were incubated with the extracellular domain of LOX-1.
Next, biotinylated anti-LOX-1 antibody was introduced. Finally, the beads were
incubated with streptavidin-conjugated AlexaFluor® 647. A fluorescence

microscope was used to detect which beads displayed fluorescence, indicating that
the biotinylated anti-LOX-1 had bound to them, which implied that LOX-1 binding

might have occurred. Beads that displayed high fluorescence could then be isolated
to determine the exact peptoid structure on them.

Figure 6. Diagram of the modified ELISA process used to detect LOX-1 binding.

Unfortunately, because of the way the combinatorial library was synthesized

it is impossible the know the side-chain sequence, i.e. the chemical structure, of the
peptoid on any particular bead simply by looking at the bead—a bead cataloging

system was not used because it would have been prohibitively difficult. As such, a

sequencing technique must be used to determine the structures of any peptoids that
showed potential LOX-1 binding. Specifically, Edman degradation, though usually

used for sequencing peptides and proteins, has been shown to work with peptoids,
including on-resin peptoids on single beads [4]. Edman degradation procedures

were carried out using an automated peptide sequencer. Because the peptoids were
not made of amino acids, new standards had to be run before sequencing could

begin. Peptoid trimers were made from each of the five side-chains used in the
library in order to run standards.

Results and Discussion

The combinatorial library was successfully synthesized and screened for

LOX-1 binding. Of the many beads that displayed fluorescence indicating the

potential presence of LOX-1 ligands, ten that displayed relatively large signals were
selected and isolated (Figure 7). Work then began on sequencing the selected

peptoids. Unfortunately, because of time constraints and technical issues, none of

the potential LOX-1 binding peptoids were sequenced as of this writing. However,
the side-chain standards were successfully run and their characteristic retention
times were determined for the sequencer being utilized (Table 1).

Figure 7. Micrograph of fluorescing resin beads from the LOX-1 affinity screening.

Side Chain

Table 1. Characteristic retention times of the side chains.

Retention Time (min)

NSer
8.43

Nbsa

15.57

Nall

17.09

Nlys

17.75

Npip

20.77

Additionally, an on-resin peptoid of known structure was sequenced to test

the automated sequencer. This peptoid was synthesized as part of another project,
but it had the sequence Nbsa-NLys-Nbsa-Npip-Nlys, of which all the side chain

retention times had been determined as shown above. The results of sequencing
this peptoid seemed to agree with the standards; however, there was significant

noise due to the extremely low peptoid concentration on only a single resin bead,
which illustrates the difficulties of performing this type of sequencing.

Conclusions

A combinatorial peptoid library was synthesized that allowed the rapid

screening of thousands peptoid structures for LOX-1 binding. Once the selected

peptoids that displayed potential for LOX-1 binding are successfully sequenced, they
can be synthesized and cleaved from the resin for use in quantitative binding assays.
Those peptoids that display LOX-1 binding can then be further engineered to
achieve the desired characteristics.

Eventually this procedure will be repeated for the protein RAGE. Then the

peptoid ligands for LOX-1 and RAGE will be combined into a complex to act as a
targeting molecule for drug-loaded microbubbles. This technology has great
potential for simultaneously increasing the efficacy of cancer chemotherapy

treatment while also decreasing said treatment’s side effects.
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